Pfizer has confirmed its plans of cutting more pharmaceutical jobs at its Pearl River plant.

In all, the company is going to lay off 115 workers. The workers in the facility’s pharmaceutical products division will lose their jobs Dec. 17, according to a notice filed with the state Labor Department, reported recordonline.com.

As per the information available, Pfizer has already announced 601 layoffs at the site.

The company also reportedly shared that some of the layoffs announced this week were part of the 601 previously announced, but he wouldn’t say how many.

This year the company has shared that it plans to exit operations in Shanbally, Ireland, as well as biotechnology manufacturing in Pearl River, N.Y., in the United States.

Plants in Sanford, N.C., and Andover, Mass., in the US and Havant, in the United Kingdom, also expect to see reductions.

Plant Network Strategy

In May this year, Pfizer Global Manufacturing shared its plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organisation from the combined networks of Pfizer and Wyeth. This implementation of the first phase of Pfizer’s previously announced Plant Network Strategy includes recommendations to cease operations at eight manufacturing sites in Ireland, Puerto Rico, and the United States by the end of 2015, as well as to reduce operations at six other plants in Germany, Ireland, Puerto Rico, the United Kingdom, and the US.

According to Pfizer, the planned reductions will increase manufacturing efficiency and lower costs by more effectively using resources and technology, improving plant processes, eliminating excess capacity, and better aligning production with market demand. These changes will result in a global reduction of approximately 6,000 jobs over the next several years.

That time, the company also shared that Pfizer plans to cease production of consumer healthcare products at its plants in Richmond, Va., and Pearl River in the United States. The Pearl River site will remain Pfizer’s Center of Excellence for Vaccine Research and Development. Consumer Healthcare R&D also will continue in Richmond.

In both Pearl River and in Richmond, R&D jobs will be unaffected by the planned manufacturing exits.

The timing of specific exits will depend upon the complexity of operations, the amount of time required for product transfers, and other business requirements.

1. Pfizer Continues To Cut Pharmaceutical Jobs At Its Pearl River Facility
2. Pfizer To Cut More Pharmaceutical Jobs At Its Pearl River Facility
3. Pfizer To Cut 6,000 Pharmaceutical Jobs
4. Pfizer To Cut 200 Pharmaceutical Jobs At Its Pearl River Facility
5. Pfizer to cut unspecified number of pharmaceutical jobs